No Detail Found!

Optimization of empagliflozin immediate release tablets (10 mg) using central composite rotatable design with response surface methodology

Author(s)
Anas M. Hanif Department of Pharmaceutics, Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University,Karachi,Pakistan
Rabia Bushra Department of Pharmaceutics, Faculty of Pharmacy, Dow University of Health Sciences,Karachi,Pakistan
Wajiha Iffat Department of Pharmaceutics, Faculty of Pharmacy, Dow University of Health Sciences,Karachi,Pakistan
Sana Ghayas Department of Pharmaceutics, Faculty of Pharmacy, Dow University of Health Sciences,Karachi,Pakistan
Shaheen Perveen Department of Pharmaceutics, Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University,Karachi,Pakistan
Humayun Riaz Department of Pharmaceutics, Rashid Latif Medical College,Lahore,Pakistan
Shazia Alam Department of Pharmaceutics, Faculty of Pharmacy, Ziauddin University,Karachi,Pakistan
Syed Imran Ali Department of Pharmaceutics, Faculty of Pharmacy, Ziauddin University,Karachi,Pakistan
Nahlah Elkudssiah Ismail Clinical Pharmaceutics Research Unit, Faculty of Pharmacy, MAHSA University,Selangor,Malaysia
Zeb-un-Nisa Department of Pharmaceutics, Faculty of Pharmacy, Ziauddin University,Karachi,Pakistan
Abstract
Empagliflozin is a selective inhibitor of sodium glucose co-transporter II, given as mono therapy or an add-on treatment to reduce the glycated hemoglobin levels in type 2 diabetes. This work deals with designing, formulating and optimizing empagliflozin (10mg) immediate release (IR) tablets by direct compression technique using different excipients. Through central composite rotatable design (CCRD), total nine formulations (EF1-EF9) were generated by changing the composition of binder avicel PH 102® (X1) and superdisintegrant acdisol® (X2). Formulation runs with in suitable weight range and powder properties were subjected to compression. The influence of interaction of excipients on friability (Y1), hardness (Y2) and disintegration (Y3) were analyzed by fitting the polynomial quadratic model with response surface methodology (RSM). Trials EF2, EF7, EF8 and EF9 exhibited acceptable tablet attributes upon physico-chemical testing. Different dissolution models were applied to observe the in vitro drug release pattern in phosphate buffer of pH 6.8. The cumulative drug release of IR tablet batches followed the Weibull kinetics with regression coefficient (r2) values of 0.983-0.992. Empagliflozin trials were exposed to accelerated storage conditions (40±2°C/ 75±5% RH) for stability testing. Shelf life period of exposed formulations were computed in range of 22 to 25 months. Keeping in view of the results, it is concluded that the employed technique of preparation and optimization are observed to be excellent for developing immediate release empagliflozin (10mg) tablets.
Publication Details
Page(s) 1519-1525
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP4, Year: 2021

Request the full text from PASTIC

Keywords
direct compression, central composite rotatable design, Empagliflozin, Optimization, Response surface methodology
References
Acharya T,Deedwania P .2019 .Cardiovascular outcome trials of the newer anti-diabetic medications. Prog. Cardiovasc. Dis., 62(4) : 342-348.
Asif U,Sherwani AK,Akhtar N,Shoaib MH,Hanif M,Qadir MI,Zaman M .2016 .Formulation development and optimization of febuxostat tablets by direct compression method. Adv. Polym. Technol., 35(2) : 129-35.
Awotwe-Otoo D,Agarabi C,Wu GK,Casey E,Read E,Lute S,Brorson KA,Khan MA,Shah RB .2012 .Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody. Int. J. Pharm., 438(1-2) : 167-75.
Bala R,Khanna S,Pawar PK .2013 .Formulation and optimization of fast dissolving intraoral drug delivery system for clobazam using response surface methodology. J Adv Pharm Technol Res., 4(3) : 151-9.
Bushra R,Rehman A,Ghayas S,Zafar F,Ali H,Shafiq Y,Khalid F,Khan MA,Hanif A,Mustapha O .2018 .Formulation design, characterization and optimization of cinitapride (1mg) immediate release tablets using direct compression technology. Pak. J. Pharm. Sci., 31 : 2725-2731.
Chattoraj S,Sun CC .2018 .Crystal and particle engineering strategies for improving powder compression and flow properties to enable continuous tablet manufacturing by direct compression. J. Pharm. Sci., 107(4) : 968-974.
Chaudhury A,Duvoor C,Reddy-Dendi VS,Kraleti S,Chada A,Ravilla R,Marco A,Shekhawat NS,Montales MT,Kuriakose K,Sasapu A,Beebe A,Patil N,Musham CK,Lohani GP,Mirza W .2017 .Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front. Endocrinol., 8 : 1-12.
Chen H,Aburub A,Sun CC .2018 .Direct compression tablet containing 99% active ingredient-A tale of spherical crystallization. J Pharm Sci., 108(4) : 1396-1400.
Medicine Agency European .2014 .. Assessment Report of Jardiance empagliflozin. United Kingdom, : 1-99.
Frampton JE .2018 .Empagliflozin: A review in type 2 diabetes. , 78(10) : 1037-1048.
Grube A,Gerlitzki C,Brendel M C .2019 .Dissolution or disintegration-substitution of dissolution by disintegration testing for a fixed dose combination product. Drug. Dev, 45(1) : 130-8.
Hanif M,Shoaib MH,Yousaf RI,Mohammad IN,Khan Ahmad,Ali T,Sattar S T .2011 .Formulation development and optimization of nimesulide tablets by central composite design and effect of surfactants on dissolution studies. J. Pharm. Res., 4(7) : 2447-2452.
Hedrington MS,Davis SN .2015 .The role of empagliflozin in the management of type 2 diabetes by patient profile. Ther Clin Risk Manag, 11 : 739.
Hixson AW,Crowell JH .1931 .Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind. Eng. Chem, 23 : 923-31.
Hu J,Zou P,Zhang S,Zhou M,Tan X .2016 .Empagliflozin/metformin fixed-dose combination: A review in patients with type 2 diabetes. Expert. Opin, 17(18) : 2471-2477.
ICH Guidelines .2003 .Harmonised Tripartite Guideline: Stability testing of new drug substances and products Q1A (R2). International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use, Endorsed by the ICH Steering Committee at Step 4/5 of the ICH Process. , : .
Kaur V,Mehara N V .2016 .A review on: Importance of superdisintegrants on immediate release tablets. Int. J. Sci. Res, 3(2) : 39-43.
Langenbucher F .1972 .Linearization of dissolution rate curves by the Weibull distribution. J. Pharm. Pharmacol., 24 : 979-981.
Levine MJ .2017 .Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev., 13(4) : 405-423.
Lingvay I,Beetz N,Sennewald R,Schuler-Metz A,Bertulis J,Loley C,Lang B,Lippert C,Lee J,Manning LS,Terada D LS .2020 .Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgrad Med, 132(4) : 337-345.
Madgulkar A,Bhalekar M,Swami M M .2009 .In vitro and in vivo studies on chitosan beads of losartan duolite AP143 complex, optimized by using statistical experimental design. AAPS Pharm Sci.Tech, 10(3) : 743.
Mor J,Chauhan P,Jalwal P .2016 .Development and evaluation of oral fast dissolving tablets of lornoxicam using superdisintegrants-A comparative study. J. Pharm. Innov., 5(7) : 1-7.
Mostafa HF,Ibrahim MA,Sakr A .2013 .Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: Effect of formulation and process variables. Pharm Dev Technol, 18(2) : 454-63.
Nair S,Wilding JP .2010 .Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J. Clin. Endocrinol. Metab., 95(1) : 34-42.
Patel T,Patel LD,Suhagia BN,Soni T,Patel T .2014 .Formulation of fenofibrate liquisolid tablets using central composite design. Curr Drug Deliv., 11(1) : 11-23.
Patro CS,Sahu PK .2017 .Combined effect of synthetic and natural polymers in preparation of cetirizine hydrochloride oral disintegrating tablets: Optimization by central composite design. J. Pharm. (Cairo), : 8305976.
Rodbard H,Blonde L,Braithwaite S,Brett E,Cobin R,Handelsman Y,Hellman R,Jellinger PS,Jovanovic LG,Levy P,Mechanick JI,Zangeneh F JI .2007 .American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract, 13 : 1-68.
Shyamala M,Sangeeta E,Mahender L E .2016 .Method development and validation of empagliflozin by RP-HPLC in bulk and pharmaceutical dosage form. Int. J. Adv. in Pharm. Sci., 7 : 3040-3042.
Thoorens G,Krier F,Rozet E,Carlin B,Evrard B B .2015 .Understanding the impact of microcrystalline cellulose physicochemical properties on tabletability. Int. J. Pharm., 490(1-2) : 47-54.
State Pharmacopeia USP35-NF30 United .2012 .The US Pharmacopoeial Covention. , : 801-803.
Varles CG,Dixon DG,Steiner S DG .1995 .Zeroorder release from biphasic polymer hydrogels. J. Cont. Rel., 34 : 185-192.
Viswanathan P,Muralidaran Y,Ragavan G Y,Technologies Nano .2017 .Nanostructures for Oral Medicine. , : 173-201.
Yousaf AM,Naheed F,Shahzad Y,Hussain T,Mahmood T .2019 .Influence of sodium starch glycolate, croscarmellose sodium and crospovidone on disintegration and dissolution of stevia-loaded tablets. Polim Med, 49(1) : 19-26.
Zafar F,Shoaib MH,Yousuf RI,Ali H,Bushra R .2018 .Development and optimization of intermediate release ketoprofen tablets by central composite design. Pak. J. Pharm. Sci., 31(5) : 1827-1836.
Mao S Zhang L .2016 .Applications of quality by design (QbD) and its tools in drug delivery. Asian J. Pharm Sci., 11 : 144-145.
Zhang Y,Huo M,Zhou J,Zou A,Li W,Yao C,Xie S C .2010 .DD Solver: An add-in program for modeling and comparison of drug dissolution profiles. AAPS J, 12(3) : 263-71.
0

Citations

0

Downloads

8

Views